Table 1.
Recipient | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | |||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Bx | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 2 | |||
Day Post-transplant | 24 | 10 | 10 | 12 | 13 | 11 | 12 | 13 | 10 | 10 | 13 | 16 | |||
Serum Cr | At Bx | 1.4 | 4.8 | 4.2 | 1.8 | 4.5 | 2.5 | 2.1 | 4.1 | 2.3 | 1.6 | 2.0 | 9.0 | ||
Peak | 1.4 | 11.9 | 8.3 | 3.7 | 7.2 | 5.8 | 6.7 | 4.8 | 4.6 | 15.4 | |||||
Last | 1.3 | 2.0 | 2 | 1.8 | 2.0 | 1.6 | 0.7 | 3 | 1.1 | 1.7 | |||||
Time | 7 y | 6.5 | 2 m | 3 y | 4 y | 1 y | 1 y | 6 mo | 6 mo | 6 mo | |||||
Symptoms | None | Fever, fluid retention | Fever, fluid retention | Minor fever, fluid retention | Minor fever, fluid retention | Minor fluid retention | Minor fluid retention | No symptoms | Minor fluid retention | Minor fever, minor fluid retention | |||||
Treatment | No additional treatment | Steroid pulse | ATG, PE, Rituxan, IVIG | Steroid pulse x3 | ATG, PE, Rituxan | No additional treatment | ATG, PE x3 | No additional treatment (ATG later) | No additional treatment | ATG; stopped tacrolimus | |||||
Banff Acute Rejection Category | None | None | AHR | None | AHR | None | ACR2 | None | None | None | None | ACR2 | |||
Light Microscopy | PTC Congestion | - | +++ | +++ | + | +++ | ++ | +++ | ++ | ++ | ++ | + | +++ | ||
Hemorrhage | - | +++ | ++++ | + | ++ | + | +++ | ++ | + | - | - | +++ | |||
Edema | - | +++ | + | + | + | + | +++ | ++ | + | - | - | ++ | |||
Tubular Injury | - | +++ | +++ | + | + | + | +++ | + | + | - | + | +++ | |||
Tubulitis4 | - | - | - | - | - | - | + | - | - | - | - | + | |||
Interstitial Infiltrate5 | - | - | | - | - | - | - | - | - | - | - | + | |||
Glomerulitis | - | - | + | + | + | - | ++ | - | + | - | - | ++ | |||
Endarteritis6 | - | - | - | - | - | - | + | - | - | - | - | ++ | |||
Immunofluorescence C4d PTC | - | - | >50% | - | >50% | - | - | - | - | 3–5% | - | - | |||
Electron microscopy | Peritubular Capillaries | Endothelium | Loss | +++ | ++ | - | - | ++ | - | + | ++ | ||||
Activation | ++ | ++ | + | + | ++ | + | + | ++ | |||||||
Fibrin and/or platelets | ++ | ++ | - | - | + | - | + | +++ | |||||||
Cells | RBC | RBC | - | RBC | RBC | - | - | RBC, N | |||||||
Glomeruli | Endothelium | Loss | - | ++ | ++ | NA | + | + | + | + | |||||
Activation | + | + | ++ | ++ | + | ++ | ++ | ||||||||
Foot process effacement | 0 | + | + | +++ | + | + | + |
No acute graft dysfunction.
Retransplanted under conventional therapy and stable at 6 yrs.
Developed TMA attributed to calcineurin inhibitor toxicity and currently on dialysis.
Tubulitis: -, none; + up to 2 lymphocytes/tubule;
Interstitial inflammation, -, none, +, up to 10%
Arteritis: +, one artery, ++ more than one artery.
Abbreviations: ATI, acute tubular injury; ACR2, acute cellular rejection, Banff type 2; AHR, acute humoral rejection; Bx: biopsy; PTC: peritubular capillary, TMA, thrombotic microangiopathy; RBC red blood cells, NA, not applicable, ATG, anti-thymocyte globulin; PE, plasmapheresis; N, neutrophils.